GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » 908 Devices Inc (NAS:MASS) » Definitions » Beneish M-Score

908 Devices (908 Devices) Beneish M-Score : -2.81 (As of May. 12, 2024)


View and export this data going back to 2020. Start your Free Trial

What is 908 Devices Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.81 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for 908 Devices's Beneish M-Score or its related term are showing as below:

MASS' s Beneish M-Score Range Over the Past 10 Years
Min: -2.97   Med: -1.86   Max: 5.06
Current: -2.81

During the past 6 years, the highest Beneish M-Score of 908 Devices was 5.06. The lowest was -2.97. And the median was -1.86.


908 Devices Beneish M-Score Historical Data

The historical data trend for 908 Devices's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

908 Devices Beneish M-Score Chart

908 Devices Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - -1.34 3.47 -2.66

908 Devices Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.06 3.96 -2.71 -2.66 -2.81

Competitive Comparison of 908 Devices's Beneish M-Score

For the Medical Devices subindustry, 908 Devices's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


908 Devices's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, 908 Devices's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where 908 Devices's Beneish M-Score falls into.



908 Devices Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of 908 Devices for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8672+0.528 * 1.0699+0.404 * 1.0995+0.892 * 1.0562+0.115 * 0.6151
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9455+4.679 * -0.057368-0.327 * 1.0837
=-2.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $7.49 Mil.
Revenue was 9.991 + 14.351 + 14.297 + 12.094 = $50.73 Mil.
Gross Profit was 5.003 + 7.275 + 7.869 + 5.794 = $25.94 Mil.
Total Current Assets was $161.87 Mil.
Total Assets was $189.79 Mil.
Property, Plant and Equipment(Net PPE) was $8.97 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.08 Mil.
Selling, General, & Admin. Expense(SGA) was $46.07 Mil.
Total Current Liabilities was $19.33 Mil.
Long-Term Debt & Capital Lease Obligation was $3.38 Mil.
Net Income was -10.917 + -7.429 + -7.093 + -9.346 = $-34.79 Mil.
Non Operating Income was -0.028 + -0.043 + 0.11 + -0.167 = $-0.13 Mil.
Cash Flow from Operations was -9.357 + -1.93 + -4.6 + -7.882 = $-23.77 Mil.
Total Receivables was $8.17 Mil.
Revenue was 9.487 + 11.643 + 15.797 + 11.106 = $48.03 Mil.
Gross Profit was 4.384 + 5.922 + 9.338 + 6.634 = $26.28 Mil.
Total Current Assets was $187.95 Mil.
Total Assets was $218.41 Mil.
Property, Plant and Equipment(Net PPE) was $10.62 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.98 Mil.
Selling, General, & Admin. Expense(SGA) was $46.14 Mil.
Total Current Liabilities was $18.66 Mil.
Long-Term Debt & Capital Lease Obligation was $5.46 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(7.486 / 50.733) / (8.173 / 48.033)
=0.147557 / 0.170154
=0.8672

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(26.278 / 48.033) / (25.941 / 50.733)
=0.547082 / 0.511324
=1.0699

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (161.868 + 8.969) / 189.791) / (1 - (187.945 + 10.624) / 218.407)
=0.099868 / 0.09083
=1.0995

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=50.733 / 48.033
=1.0562

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.981 / (1.981 + 10.624)) / (3.078 / (3.078 + 8.969))
=0.15716 / 0.255499
=0.6151

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(46.074 / 50.733) / (46.137 / 48.033)
=0.908166 / 0.960527
=0.9455

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3.38 + 19.33) / 189.791) / ((5.459 + 18.656) / 218.407)
=0.119658 / 0.110413
=1.0837

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-34.785 - -0.128 - -23.769) / 189.791
=-0.057368

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

908 Devices has a M-score of -2.81 suggests that the company is unlikely to be a manipulator.


908 Devices Beneish M-Score Related Terms

Thank you for viewing the detailed overview of 908 Devices's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


908 Devices (908 Devices) Business Description

Traded in Other Exchanges
N/A
Address
645 Summer Street, Boston, MA, USA, 02210
908 Devices Inc manufactures medical devices. It has developed an innovative suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets.
Executives
Griffith Joseph H. Iv officer: Chief Financial Officer 68 ELM STREET, HOPKINTON MA 01748
Christopher D. Brown officer: Chief Technology Officer C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Kevin J. Knopp director, officer: President and CEO C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Michael S. Turner officer: VP, General Counsel C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Maura Fitzpatrick officer: VP, Product Management & Mktg 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Mark Spoto director C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Michele Fournier officer: Chief People Officer 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Trent A. Basarsky officer: Vice President, Commercial C/O PROTEINSIMPLE, 3040 OAKMEAD VILLAGE DRIVE, SANTA CLARA CA 95051
John Kenneweg officer: Vice President, Government C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Anthony Hunt director 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
Marcia Eisenberg director C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Jeffrey P. George director C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Fenel M Eloi director C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452
Keith Crandell director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631